Aptose Biosciences Files 8-K with Exhibits
Ticker: APTOF · Form: 8-K · Filed: Jul 26, 2024 · CIK: 882361
Sentiment: neutral
Topics: filing, exhibits, corporate-reporting
Related Tickers: APTO
TL;DR
APTO filed an 8-K on 7/26/24, mostly exhibits. Nothing major.
AI Summary
Aptose Biosciences Inc. filed an 8-K on July 26, 2024, reporting financial statements and exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and headquartered in Toronto.
Why It Matters
This filing indicates routine corporate reporting, providing updated information on the company's financial status and exhibits for the period ending July 26, 2024.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting financial statements and exhibits, not indicating any immediate material changes or events.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- July 26, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of July 26, 2024.
What is the exact name of the registrant?
The exact name of the registrant is Aptose Biosciences Inc.
In which jurisdiction is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
What were some of Aptose Biosciences Inc.'s former company names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
What is the SEC file number for Aptose Biosciences Inc.?
The SEC file number for Aptose Biosciences Inc. is 001-32001.
Filing Stats: 393 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2024-07-26 16:30:11
Filing Documents
- f8k_072624.htm (8-K) — 23KB
- exh_991.htm (EX-99.1) — 37KB
- exh991_01.jpg (GRAPHIC) — 37KB
- exh991_02.jpg (GRAPHIC) — 144KB
- exh991_03.jpg (GRAPHIC) — 70KB
- exh991_04.jpg (GRAPHIC) — 108KB
- exh991_05.jpg (GRAPHIC) — 105KB
- exh991_06.jpg (GRAPHIC) — 104KB
- exh991_07.jpg (GRAPHIC) — 121KB
- exh991_08.jpg (GRAPHIC) — 111KB
- exh991_09.jpg (GRAPHIC) — 122KB
- exh991_10.jpg (GRAPHIC) — 87KB
- exh991_11.jpg (GRAPHIC) — 72KB
- exh991_12.jpg (GRAPHIC) — 39KB
- exh991_13.jpg (GRAPHIC) — 90KB
- exh991_14.jpg (GRAPHIC) — 126KB
- exh991_15.jpg (GRAPHIC) — 107KB
- exh991_16.jpg (GRAPHIC) — 111KB
- exh991_17.jpg (GRAPHIC) — 75KB
- exh991_18.jpg (GRAPHIC) — 130KB
- exh991_19.jpg (GRAPHIC) — 94KB
- exh991_20.jpg (GRAPHIC) — 13KB
- 0001171843-24-004181.txt ( ) — 2853KB
- apto-20240726.xsd (EX-101.SCH) — 3KB
- apto-20240726_def.xml (EX-101.DEF) — 26KB
- apto-20240726_lab.xml (EX-101.LAB) — 35KB
- apto-20240726_pre.xml (EX-101.PRE) — 24KB
- f8k_072624_htm.xml (XML) — 6KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. 99.1 Aptose Corporate Presentation - July 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: July 26, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer